One or more aqueous, near infrared emitting, high yield, highly photoluminescent, stable quantum dots conjugated to one or more biomarkers specific moieties. The conjugated quantum dots have an enhanced detection sensitivity and selectivity and may be formed using a novel and efficient method for conjugating one or more biomarker specific moieties to the quantum dots. The invention is further directed to a method for using the conjugated quantum dots for cancer detection in the margin of excised tissue.

An aqueous approach to synthesize capped SnS quantum dots (QDs) followed by optional capping molecule extension by attaching one or more extending molecules to the capping molecule via peptide bond formation at elevated temperature. The capped SnS QDs may have a capping molecule:Sn:S molar ratio of 16:3:1 to 16:12:1. A suspension of SnS QDs was heat-treated at 200 C. for 0.5-4 hrs. The obtained SnS QDs showed an NIR emission peak at 820-835 nm with an excitation wavelength at 690 nm. The as synthesized SnS QDs were found to have high positive zeta potential of 30 mV and thus were toxic to cells. By neutralizing the SnS QDs the cytotoxicity was reduced to an accepted level. The heat-treatment step can be obviated by adding a glycerol solution containing S.sup.2 anions and capping molecule to a glycerol solution of Sn.sup.2+ ions.

A multi-component nanochain for use in diagnostic and therapeutic applications includes at least three nanoparticles linked together to form the nanochain. At least one nanoparticle of the nanochain has an asymmetric surface chemistry defined by asymmetrically disposed first linkers and second linkers. The nanoparticles are linked to form the nanochain by linking first linkers and/or second linkers disposed on separate nanoparticles.

Imaging based detection of changes in extracellular neurotransmitter concentration in living tissue is achieved using novel nanotube-based sensors. The sensors are functionalized, neurocompatible single-walled carbon nanotubes (SWNT) comprising an adsorbed neurotransmitter analyte selective polynucleotide.

A novel near-IR emitting cationic silver chalcogenide quantum dot with a mixed coating wherein the coating comprises of at least 2 different types of materials and is capable of luminescence at the desired near IR bandwidth at wavelengths of 800-850 nm. The quantum dot is fabricated via an advantageous single-step, homogeneous, aqueous method at a low temperature resulting a near IR emitting semiconductor quantum dot with high Quantum Yield, high transfection with low toxicity. The quantum dots may be used in medical imaging, tumor detection, drug delivery and labeling as well as in quantum dot sensitized solar cells.

A light emitter is formed from nanoparticles including a compound semiconductor containing an Ag component, In component, and Se component. The peak wavelength of the emission intensity falls within the range of 700 to 1400 nm, and the half-value width H for the peak wavelength is 100 nm or less. The light emitted is configured to emit strong light in the near-infrared region, and which is capable of detecting biological information, and is preferred for bioimaging.

In one aspect, compositions comprising copper-silica (CuSiO.sub.2) core-shell nanoparticles are described herein. The core-shell nanoparticles comprise copper (Cu) core components and silica (SiO.sub.2) shell components encapsulating the core components. In some embodiments, the nanoparticle compositions comprise a continuous aqueous phase and a population of copper-silica (CuSiO.sub.2) core-shell nanoparticles dispersed in the aqueous phase.

An imaging probe can include a photoluminescent carbon nanostructure configured to emit a wavelength of light detectable through living tissue, and a targeting moiety including a first binding partner configured to interact with a second binding partner.

A novel near-IR emitting cationic silver chalcogenide quantum dot with a mixed coating wherein the coating comprises of at least 2 different types of materials and is capable of luminescence at the desired near IR bandwidth at wavelengths of 800-850 nm. The quantum dot is fabricated via an advantageous single-step, homogeneous, aqueous method at a low temperature resulting a near IR emitting semiconductor quantum dot with high Quantum Yield, high transfection with low toxicity. The quantum dots may be used in medical imaging, tumor detection, drug delivery and labeling as well as in quantum dot sensitized solar cells.

The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation cost on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents.